NEW YORK, July 6 (GenomeWeb News) - Chiron has acquired oncogenomics firm Sagres Discovery, the companies said today.
Sagres Discovery, of Davis, Calif., has been using high-throughput genomic technologies to analyze mouse models of cancer. Based on the results, the company has assembled a set of oncology targets it calls the Oncogenome.
"With the wealth of targets from Sagres, we expect to be able to maximize the value of our collaboration with Xoma and our small molecule drug discovery program for the development and commercialization of new drugs for the treatment of cancer," commented Kenneth Bair, senior vice president and head of research at Chiron BioPharmaceuticals, in a statement.
Sagres had several collaborations, including with the Genome Institute of Singapore and Boehringer Ingelheim, both announced last year.
Neither company disclosed financial terms of the acquisition.